These TCRs also elicited strong immune responses against various tumor cell lines expressing both HLA-A11:01 and the KRAS G12D mutation, including PANC-1, HeLa, HPAF-II, and HuCCT1 [35–37]. This evidence concerns the gene KRAS and neoplasm.